Active, not recruiting
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT05675579
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States